All Research
Page 1 of 10 · 219 reports
Okta is the largest independent identity-security vendor, selling workforce and customer identity (SSO, MFA, governance, privileged access, and emerging AI-agent controls) as recurring subscriptions; FY2026 subscription revenue was $2.855 billion of $2.919 billion total. Growth has cooled to about 11% with FY2027 guidance of just 9–10%, but free cash flow is now substantial, with $884 million of operating cash flow in FY2026, so the real debate is whether Okta is a sturdier compounder or a maturing core squeezed by Microsoft's bundle and a still-healing trust scar. Rating Hold: a credible business at fair-to-moderate value with limited margin of safety, with a genuine moat and real cash but slower growth and bundling pressure that cap the rerating upside.
Falling oil prices eased inflation pressure and the Dow set another record high, but a pullback in AI and semiconductors weighed on the S&P and Nasdaq, leaving the market in an elevated, divided state ahead of the Fed decision. Rating Watch: a high-level rotation rather than a trend break, where capital shifts between oil-beneficiary traditional sectors and crowded AI/chip names.
NAURA is China's broadest listed domestic wafer-fab equipment platform, selling into etch, deposition, cleaning and more, with 2025 process-equipment revenue of CNY 36.73 billion. Real usage clearly carries the story, with two tool families each topping CNY 10 billion in 2025, yet at roughly 48x forward earnings the stock already discounts years of near-flawless execution. Rating Watch: a genuine national champion worth owning on pullbacks into the CNY 500-580 fair-buy band, not chasing because the localization story is true.
The Iran framework deal pushed down oil prices and rate risk, with the Nasdaq and semiconductors leading the advance as U.S. equities staged a risk-appetite repair on still-divided breadth. The core thesis is that compressed geopolitical risk premium drove the rally, but leadership concentrated in AI and semis rather than broadening evenly. Rating Watch: a relief rally to monitor until the Fed, oil, and fresh semiconductor highs confirm the move.
AstraZeneca is an innovative-drug giant built around oncology and rare disease, monetizing through R&D and global commercialization. 2025 revenue reached 58.739 billion USD, with the growth engine shifting toward oncology (+20% year over year) and rare disease (+19%) to offset pressure on legacy CVRM drugs, leaving its multi-platform structure more balanced than single-engine peers. Rating Hold: at the current 178.75 USD the stock still trades at a premium to conservative intrinsic value with no meaningful margin of safety, a high-quality name that has entered a delivery-pressure phase.
Reddit is a UGC platform built around subreddit communities, led by advertising and also selling AI training data, with 2025 revenue of $2.203 billion and ads making up roughly 94%. Growth is strong but the worries run alongside it: U.S. DAUq grew only 7% in Q1 2026 while logged-out traffic rose 26%, and Google AI summaries are eroding the search distribution funnel. The stock has already pulled back about 40% from its $270.71 peak to $162.10. Rating Hold: the story is big enough but single-point risk is high; wait for a pullback to the $110-130 ideal buy zone.
HEICO got its start in FAA-PMA replacement parts and high-reliability electronics, and has turned the aviation aftermarket into a compounding growth platform through a steady cadence of tuck-in acquisitions. In FY2025 its two segments, Flight Support and Electronic Technologies, contributed roughly 3.117 billion and 1.413 billion dollars of revenue with first-rate quality; but at 331.61 dollars the stock trades near 50 times earnings, far above peer TransDigm at about 31 times, leaving almost no margin of safety. Rating Hold: a great company at an expensive price, worth buying back in the 235 to 260 dollar ideal-entry zone.
Meitu is an AI visual-tools company that uses imaging apps as its entry point and monetizes through subscriptions and usage-based fees, with a total market cap of roughly HK$21.11 billion. Its core subscription business is already working and gross margin runs above 70%, but usage-based revenue, productivity ARR, and overseas paid penetration still have to prove themselves quarter by quarter, while rising compute costs test its pricing power. Rating Hold: at the current HK$4.64 the stock sits in an acceptable holding range, and below HK$4 it becomes more attractive for new money.
Anji Technology makes CMP polishing slurry and functional wet electronic chemicals, and is a core play on domestic substitution in semiconductor materials, with 2025 revenue of 2.504 billion yuan. Import substitution is converting strongly, but at roughly 230 yuan and a PE above 60x the market has already priced in second-curve businesses such as electroplating solutions, leaving no margin of safety against a conservative intrinsic value. Rating Hold: the fair buying range is 135 to 145 yuan, and a more visible pullback is needed before building a position in tranches.
Hitachi is Japan's integrated electrical-machinery champion, now reshaped into an infrastructure platform built on three engines: grid energy, digital (Lumada), and rail mobility. In FY2025 group revenue reached 10.59 trillion yen and the adjusted EBITA margin hit a record 12.4%, with energy backlog of roughly 10 trillion yen and data center orders up more than 150% year over year. Rating Hold: the growth inflection is confirmed, but the current price sits at about neutral intrinsic value with no clear margin of safety.
Kuaishou is China's second-largest short-video platform, monetizing through advertising, e-commerce, and live streaming, while betting on Kling AI video as a second growth curve. In 2025 adjusted net profit reached 20.65 billion RMB on a P/E of roughly 9.9x, yet Q1 net margin fell from 14.0% to 10.0% even as Kling's single-quarter revenue topped 650 million RMB and grew over 300%. Rating Cautious Buy: the core business is cheaply valued with solid cash flow, and the Kling option is not yet fully priced in.
Kioxia Holdings is a NAND/SSD memory maker spun out of Toshiba and deeply co-manufacturing with SanDisk, and one of the few pure storage plus AI-inference plays available in the Japanese market. FY2026 revenue surged to ¥2.34 trillion with explosive profit, but the same-day market cap of roughly ¥44.36 trillion implies a TTM P/E near 79x, and the profit peak rests mainly on an ASP spike rather than volume, leaving the current price above even the optimistic valuation ceiling. Rating Avoid: the operational repair is real, but the stock has priced in AI and de-cyclicalization far too early.
U.S. equities closed higher on a sharp drop in oil, SpaceX's first-day listing, and improving breadth, but rates and the pressure on software AI monetization still capped any chase higher. Money rotated risk-on without indiscriminately bidding up tech: Adobe fell on AI monetization concerns and a CFO departure, while the chip chain held up on AMD and Nvidia's China Vera CPU news. Rating Watch: a one-day risk-appetite repair driven by oil and a single IPO needs breadth, rates, and energy prices to confirm before it becomes a trend, so track cleaner cash-flow names over the AI narrative chase.
Atlassian is a collaboration and development software subscription vendor built around Jira and Confluence, with FY2025 revenue of 5.215 billion USD and Cloud accounting for roughly two-thirds. Q3 FY2026 revenue grew 32% year over year, but about 50 million USD of that was the pull-forward recognition of Data Center wind-down, and stock-based compensation still consumes 25 points of operating margin. Rating Hold: Cloud and ITSM momentum remain strong, but the pull-forward recognition and the test that AI poses to the per-seat model have not yet cleared.
WuXi Biologics is a global biologics CRDMO platform that uses a win-the-molecule model to carry early-stage programs all the way to late-stage commercial manufacturing, converting them into sticky back-end revenue. 2025 revenue reached RMB 21.79 billion, up 16.7% year on year, with back-end manufacturing already at 43.4% of revenue; yet 58.1% of revenue comes from North America, and the valuation is pinned at roughly 22x trailing earnings by a BIOSECURE-driven geopolitical discount. Rating Hold: manufacturing delivery is proven, but listing risk is not yet resolved and the margin of safety remains thin.
RoboSense is a LiDAR supplier driven by the twin engines of automotive ADAS and robotics, using in-house chips to cut costs and scale up volume. In 2025 it posted revenue of 1.941 billion yuan and lifted gross margin to 26.5%, turning its first-ever quarterly profit in Q4; in Q1 2026 gross margin slipped back to 21.7% and it lost another 63.32 million yuan, so the scale inflection has arrived but the profit inflection is not yet proven. Rating Watch: robotics volume is materializing, but durable profitability still needs validating, and the current price sits above the ideal buy zone of HKD 19 to 23.
Keyence is a Japanese industrial-automation supplier driven by a fabless, direct-sales model and a high cadence of new products, centered on FA sensors, machine vision, and measurement instruments. FY2026 revenue rose 10.4% year over year with a 51% operating margin and continued overseas expansion, yet at the current price of 72,260 yen the trailing P/E is about 39.4x and the owner-earnings yield has fallen below the Japanese 10-year government bond. Rating Hold: business quality is top-tier, but the current price already largely reflects that quality and growth.
Baidu is a Chinese internet platform anchored on search-advertising cash flow and pivoting toward AI cloud and Robotaxi. In Q1 2026 AI-related revenue reached 13.6 billion yuan, clearing half of the core business for the first time, with AI cloud infrastructure up 79% year over year, even as online marketing fell 22% and profit conversion remains unproven. Rating Watch: the AI cloud is accelerating, but the advertising decline and unproven profit conversion have yet to deliver an adequate margin of safety.
A daily read on U.S. equities. Cooling Iran risk pulled oil lower and sparked a tech rebound, lifting the three major indices to their best single-day showing since April, yet a hot PPI print and split software stocks still cap any appetite to chase. Rating Watch: a relief bounce on receding geopolitical risk, not a confirmed all-clear on rates or conflict.
argenx is the global leader in antibody therapies for rare autoimmune disease and the first-in-class pioneer of the FcRn-inhibitor field. Its core product Vyvgart (efgartigimod) is now approved across three indications (gMG, CIDP globally plus ITP in Japan), with roughly 19,000 patients on therapy, FY2025 net sales of USD 4.15 billion (+90%), and a first-ever positive operating profit of USD 1.05 billion. Vision 2030 targets 50,000 patients, 10 labels, and 5 Phase III molecules. Rating Watch: a genuinely strong asset whose USD 882.41 price already prices in smooth execution, so the entry window opens only on a pullback to USD 720 or below.
Disco is Japan's leading back-end semiconductor equipment maker, specializing in the three high-precision, mission-critical steps of wafer dicing, grinding, and polishing, with an integrated equipment-plus-consumables-plus-service model that benefits deeply from AI/HBM and advanced packaging demand. FY2025 net profit was roughly 135.5 billion yen, overseas sales made up 87.6% of the total, the balance sheet carries long-term net cash, gross margins are exceptionally high, and management runs the business against a four-year RORA discipline. Rating Watch: a superb business whose current price already prepays years of high-growth, high-margin, AI-driven expectations, leaving little margin of safety.
Sea Limited is Southeast Asia's largest internet platform, headquartered in Singapore and listed on the NYSE, running three engines in parallel: Shopee (e-commerce), Monee (digital finance), and Garena (gaming, with Free Fire). FY2025 revenue reached USD 22.9B (+36%) and GAAP net profit USD 1.6B (+260%), the first time it turned a profit at scale; Shopee holds roughly 53% of Southeast Asia GMV, ranking first across all six markets, while Monee's loan book grew 71% in a year to USD 9.9B. Q1 2026 revenue accelerated further to +47%, but GAAP EPS of 0.67 missed expectations, and the stock has halved from its 52-week high of 199 to around 84. Rating Watch: a fundamentally strong, fairly valued compounder whose upside hinges on Q2/Q3 confirmation that profit quality is holding.
An oversold bounce in chip stocks held up the Nasdaq and S&P 500, but the Dow finished lower and breadth was uneven, leaving the market in sector-rotation mode ahead of CPI. The bounce was concentrated in beaten-down AI and semiconductor names rather than a broad-based advance, with rates and oil still applying pressure. Rating Watch: a single-day chip rebound looks more like a technical repair after last Friday's selloff than a fresh trend confirmation, so wait for breadth, rates, and oil to align.
Eurofins Scientific, founded in 1987 by Gilles Martin in Nantes, France and headquartered in Luxembourg, is the world's largest testing, inspection and certification (TIC) leader, spanning food, environment, pharma, clinical diagnostics and consumer products, with roughly 64,000 employees and 900+ laboratories across 50+ countries; FY2025 revenue was EUR 7.30 B (+5.0% reported / +4.1% organic), adjusted EBITDA margin 22.5% (mature business 24.3%) and EPS EUR 2.31 (+24%), while the Martin family holds 32.9% economic interest / 65.8% voting power through Analytical Bioventures. Following Muddy Waters' June 2024 short report alleging self-dealing—which the company fully rebutted—the market's governance discount has yet to fully clear. Rating Watch: a high-quality TIC leader that is reasonably-to-richly valued and awaits a pullback rather than entry at the current price.